Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISIS 183750 + irinotecan
- Development stage
- Unknown
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
ISIS 183750 + irinotecan is a combination therapy evaluated primarily for advanced solid tumors and refractory colorectal cancer. ISIS 183750 is a second-generation antisense oligonucleotide designed to inhibit the production of eukaryotic translation initiation factor 4E (eIF4E), an oncogene dysregulated in many cancers. By reducing eIF4E mRNA and protein levels, it aims to suppress tumor cell proliferation. Irinotecan is a topoisomerase I inhibitor chemotherapy agent that induces DNA damage in rapidly dividing cells, leading to cell death. Preclinical studies demonstrated additive antiproliferative effects when these agents are combined. Clinical trials have shown that this combination can achieve disease stabilization in patients with refractory colorectal cancer who had progressed on prior therapies[1][3][2].
- Brand names
- Campto (for irinotecan)
- Other names
- eIF4E antisense oligonucleotide + irinotecanISIS EIF4ERX + irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)EIF4E (Eukaryotic translation initiation factor 4E)
Beyond the preview
Go deeper on ISIS 183750 + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISIS 183750 + irinotecan.